138 related articles for article (PubMed ID: 26828595)
1. Elevated Serum Concentration of Chitinase 3-Like 1 is an Independent Prognostic Biomarker for Poor Survival in Lung Cancer Patients.
Wang J; Sheng Z; Yang W; Cai Y
Cell Physiol Biochem; 2016; 38(2):461-8. PubMed ID: 26828595
[TBL] [Abstract][Full Text] [Related]
2. The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis.
Huang Y; Wei S; Jiang N; Zhang L; Wang S; Cao X; Zhao Y; Wang P
BMC Cancer; 2018 Dec; 18(1):1235. PubMed ID: 30526532
[TBL] [Abstract][Full Text] [Related]
3. Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer.
Xu CH; Yu LK; Hao KK
PLoS One; 2014; 9(5):e96384. PubMed ID: 24801872
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic Value of PLR in Lung Cancer, a Meta-analysis Based on Results from a Large Consecutive Cohort.
Ding N; Pang Z; Shen H; Ni Y; Du J; Liu Q
Sci Rep; 2016 Oct; 6():34823. PubMed ID: 27703265
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of chitinase 3-like 1 is a prognosis marker for non-small cell lung cancer correlated with tumor angiogenesis.
Wang XW; Cai CL; Xu JM; Jin H; Xu ZY
Tumour Biol; 2015 Feb; 36(2):901-7. PubMed ID: 25304157
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of serum adipokines levels in lung cancer.
Kerenidi T; Lada M; Tsaroucha A; Georgoulias P; Mystridou P; Gourgoulianis KI
Med Oncol; 2013 Jun; 30(2):507. PubMed ID: 23430445
[TBL] [Abstract][Full Text] [Related]
7. Chitinase 3 like 1 is associated with tumor angiogenesis in cervical cancer.
Ngernyuang N; Francescone RA; Jearanaikoon P; Daduang J; Supoken A; Yan W; Shao R; Limpaiboon T
Int J Biochem Cell Biol; 2014 Jun; 51():45-52. PubMed ID: 24691276
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: Review and meta-analysis.
Wang Z; Wang Y; Zhang X; Zhang T
Clin Chim Acta; 2018 Nov; 486():303-310. PubMed ID: 30138620
[TBL] [Abstract][Full Text] [Related]
9. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.
Hinsinger G; Galéotti N; Nabholz N; Urbach S; Rigau V; Demattei C; Lehmann S; Camu W; Labauge P; Castelnovo G; Brassat D; Loussouarn D; Salou M; Laplaud D; Casez O; Bockaert J; Marin P; Thouvenot E
Mult Scler; 2015 Sep; 21(10):1251-61. PubMed ID: 25698171
[TBL] [Abstract][Full Text] [Related]
10. High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer.
Choi IK; Kim YH; Kim JS; Seo JH
Acta Oncol; 2010 Aug; 49(6):861-4. PubMed ID: 20553098
[No Abstract] [Full Text] [Related]
11. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts.
Kornblit B; Hellemann D; Munthe-Fog L; Bonde J; Strøm JJ; Madsen HO; Johansen JS; Garred P
Immunobiology; 2013 Oct; 218(10):1227-34. PubMed ID: 23706599
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.
Zhao S; Qiu Z; He J; Li L; Li W
Int J Clin Exp Pathol; 2014; 7(10):6694-704. PubMed ID: 25400749
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Pretreatment D-Dimer Level in Small-Cell Lung Cancer: A Meta-Analysis.
Li J; Wang Y; Li J; Che G
Technol Cancer Res Treat; 2021; 20():1533033821989822. PubMed ID: 33563114
[TBL] [Abstract][Full Text] [Related]
14. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
[TBL] [Abstract][Full Text] [Related]
15. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.
Cantó E; Tintoré M; Villar LM; Costa C; Nurtdinov R; Álvarez-Cermeño JC; Arrambide G; Reverter F; Deisenhammer F; Hegen H; Khademi M; Olsson T; Tumani H; Rodríguez-Martín E; Piehl F; Bartos A; Zimova D; Kotoucova J; Kuhle J; Kappos L; García-Merino JA; Sánchez AJ; Saiz A; Blanco Y; Hintzen R; Jafari N; Brassat D; Lauda F; Roesler R; Rejdak K; Papuc E; de Andrés C; Rauch S; Khalil M; Enzinger C; Galimberti D; Scarpini E; Teunissen C; Sánchez A; Rovira A; Montalban X; Comabella M
Brain; 2015 Apr; 138(Pt 4):918-31. PubMed ID: 25688078
[TBL] [Abstract][Full Text] [Related]
16. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
17. HE4 expression in lung cancer, a meta-analysis.
Zhong H; Qian Y; Fang S; Yang L; Li L; Gu W
Clin Chim Acta; 2017 Jul; 470():109-114. PubMed ID: 28499820
[TBL] [Abstract][Full Text] [Related]
18. High circulating VEGF level predicts poor overall survival in lung cancer.
Hu P; Liu W; Wang L; Yang M; Du J
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1157-67. PubMed ID: 23552871
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients.
Gu X; Sun S; Gao XS; Xiong W; Qin S; Qi X; Ma M; Li X; Zhou D; Wang W; Yu H
Sci Rep; 2016 Mar; 6():23893. PubMed ID: 27025911
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients.
Wang XF; Zhu YT; Wang JJ; Zeng DX; Mu CY; Chen YB; Lei W; Zhu YH; Huang JA
PLoS One; 2017; 12(9):e0185168. PubMed ID: 28934305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
